Drug Delivery Business News, reports today that the company launched its FDA-cleared OTC CGM system for weight management.

Palo Alto, California-based Signos integrated the Dexcom Stelo OTC continuous glucose monitor (CGM) with an AI-powered platform for deciphering unique metabolisms. It aims to help people see how food choices, timing, activity, stress and sleep affects their bodies in real time.

The comprehensive metabolic health platform includes proprietary AI with the CGM sensor to provide real-time data and recommendations for weight management. Signos aims for its metabolic-led solution to reverse prediabetes and aid those on their weight loss journey.